ArticleAmerican journal of nuclear medicine and molecular imaging2025
CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma.
Article in American journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers.Frontiers in immunology · 2026Review
- Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.Case reports in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC), accounting for 65%-70%, is the most common subtype of renal cell cancers. Contrast-enhanced CT and MRI are still the predominant diagnostic modalities for renal carcinoma in clinical practice, but they cannot provide accurate diagnosis and staging, and molecular information related to tumor microenvironment. Carbonic anhydrase IX (CAIX), a transmembrane metalloenzyme on the cell surface and associated with hypoxia within the tumor, is emerging as a potential molecular target for both diagnosis and therapy in ccRCC. CAIX-targeted molecular imaging enables non-invasive visualization of ccRCC and guides treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.